Next Generation Therapeutics for Repair of Human Organs and Tissues – Bioquark [transcript]
Tag: biotechnology
Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Posted in aging, bioengineering, biotech/medical, disruptive technology, DNA, genetics, health, life extension, posthumanism, science | Leave a Comment on Bioquark Inc. and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e. gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Bioquark Inc. Announces Approval of Bioquantine Food Ingredients in Eurasian Customs Union
Posted in aging, biotech/medical, business, disruptive technology, food, genetics, health, life extension, science, transhumanism | Leave a Comment on Bioquark Inc. Announces Approval of Bioquantine Food Ingredients in Eurasian Customs Union
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm
Bioquark Inc. Announces Commercial Cosmetology Relationship with Forest Organics LLC & I-Beauty Charm LLC
Posted in aging, biotech/medical, business, chemistry, disruptive technology, genetics, health, life extension, science | Leave a Comment on Bioquark Inc. Announces Commercial Cosmetology Relationship with Forest Organics LLC & I-Beauty Charm LLC
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel, natural bio-products for health, wellness and rejuvenation, has entered a collaboration whereby Forest Organics LLC & I-Beauty Charm LLC, a unique, integrated facial and body cosmetology facility, and their state-licensed, highly skilled skin care specialists, will be utilizing novel, natural Bioquantine™ extract complexes as part of their spa procedures, as well as providing consumer access to a range of proprietary skin care products (http://www.forestorganics.life).
“We are very excited about this first company collaboration in the area of beauty care and cosmetology,” said Ira S. Pastor, CEO, Bioquark Inc. “It is another step forward towards the wide applicability of our natural combinatorial bio-products, across a broad range of health and wellness segments, as well as future franchise opportunities.”
The integrated Forest Organics LLC & I-Beauty Charm LLC model was conceived by local Tampa business women, Nadia Goetzinger and Tatyana Reshetnikova, to offer a new generation of products and services related to skin beautification and rejuvenation.
“We look forward to working closely with Bioquark Inc. on this initiative and providing an exclusive range of services and products to customers throughout the greater Tampa metropolitan area,” said Ms. Goetzinger”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biopharmaceutical candidates, as well as non-Rx products for the global consumer health and wellness market segments.
About Forest Organics LLC & I-Beauty Charm LLC
Forest Organics LLC & I-Beauty Charm LLC operate a unique, integrated facial and body cosmetology facility providing novel rejuvenative spa and cosmetology services and products.
Bringing The Dead Back To Life — Reanima Project / Bioquark Inc. Media Coverage
Posted in aging, bioengineering, biological, cryonics, disruptive technology, futurism, health, life extension, neuroscience, transhumanism | Leave a Comment on Bringing The Dead Back To Life — Reanima Project / Bioquark Inc. Media Coverage
Fox 29 — Good Day Philadelphia
http://www.fox29.com/140735577-video
NBC TV 10
CNN en Espanol
http://cnnespanol.cnn.com/video/cnnee-encuentro-intvw-joel-osorio-bioquantina-muerte-cerebral/
Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study
Posted in aging, bioengineering, biological, biotech/medical, cryonics, disruptive technology, futurism, health, life extension, neuroscience | Leave a Comment on Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study
Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.
This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.
“We are very excited about the approval of our protocol,” said Ira S. Pastor, CEO, Bioquark Inc. “With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies.”
Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.
While human beings lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, planarians, and certain fish, can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.
Additionally, recent studies on complex brain regeneration in these organisms, have highlighted unique findings in relation to the storage of memories following destruction of the entire brain, which may have wide ranging implications for our understanding of consciousness and the stability of memory persistence.
“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer’s and Parkinson’s disease,” said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.
Over the years, clinical science has focused heavily on preventing such life and death transitions and made some initial progress with suspended animation technologies, such as therapeutic hypothermia. However, once humans transition through the brain death window, currently defined by the medical establishment as “irreversible”, they are technically no longer alive, despite the fact that human bodies can still circulate blood, digest food, excrete waste, balance hormones, grow, sexually mature, heal wounds, spike a fever, and gestate and deliver a baby. It is even acknowledged by thought leaders that recently brain dead humans still may have residual blood flow and electrical nests of activity in their brains, just not enough to allow for an integrated functioning of the organism as a whole.
“We look forward to working closely with Bioquark Inc. on this cutting edge clinical initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences.
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.
“He is not here; He has risen,” — Matthew 28:6
As billions of Christians around the world are getting ready to celebrate the Easter festival and holiday, we take pause to appreciate the awe inspiring phenomena of resurrection.
In religious and mythological contexts, in both Western and Eastern societies, well known and less common names appear, such as Attis, Dionysus, Ganesha, Krishna, Lemminkainen, Odin, Osiris, Persephone, Quetzalcoatl, and Tammuz, all of whom were reborn again in the spark of the divine.
In the natural world, other names emerge, which are more ancient and less familiar, but equally fascinating, such as Deinococcus radiodurans, Turritopsis nutricula, and Milnesium tardigradum, all of whose abilities to rise from the ashes of death, or turn back time to start life again, are only beginning to be fully appreciated by the scientific world.
In the current era, from an information technology centric angle, proponents of a technological singularity and transhumanism, are placing bets on artificial intelligence, virtual reality, wearable devices, and other non-biological methods to create a future connecting humans to the digital world.
This Silicon Valley, “electronic resurrection” model has caused extensive deliberation, and various factions to form, from those minds that feel we should slow down and understand the deeper implications of a post-biologic state (Elon Musk, Steven Hawking, Bill Gates, the Vatican), to those that are steaming full speed ahead (Ray Kurzweil / Google) betting that humans will shortly be able to “transcend the limitations of biology”.
However, deferring an in-depth Skynet / Matrix discussion for now, is this debate clouding other possibilities that we have forgotten about, or may not have even yet fully considered?
Today, we find ourselves at an interesting point in history where the disciplines of regenerative sciences, evolutionary medicine, and complex systems biology, are converging to give us an understanding of the cycle of life and death, orders of magnitude more complex than only a few years ago.
In addition to the aforementioned species that are capable of biologic reanimation and turning back time, we show no less respect for those who possess other superhuman capabilities, such as magnetoreception, electrosensing, infrared imaging, and ultrasound detection, all of which nature has been optimizing over hundreds of millions of years, and which provide important clues to the untapped possibilities that currently exist in direct biological interfaces with the physical fabric of the universe.
The biologic information processing occurring in related aneural organisms and multicellular colony aggregators, is no less fascinating, and potentially challenges the notion of the brain as the sole repository of long-term encoded information.
Additionally, studies on memory following the destruction all, or significant parts of the brain, in regenerative organisms such as planarians, amphibians, metamorphic insects, and small hibernating mammals, have wide ranging implications for our understanding of consciousness, as well as to the centuries long debate between the materialists and dualists, as to whether we should focus our attention “in here”, or “out there”.
I am not opposed to studying either path, but I feel that we have the potential to learn a lot more about the topic of “out there” in the very near future.
The study of brain death in human beings, and the application of novel tools for neuro-regeneration and neuro-reanimation, for the first time offer us amazing opportunities to start from a clean slate, and answer questions that have long remained unanswered, as well as uncover a knowledge set previously thought unreachable.
Aside from a myriad of applications towards the range of degenerative CNS indications, as well as disorders of consciousness, such work will allow us to open a new chapter related to many other esoteric topics that have baffled the scientific community for years, and fallen into the realm of obscure curiosities.
From the well documented phenomena of terminal lucidity in end stage Alzheimer’s patients, to the mysteries of induced savant syndrome, to more arcane topics, such as the thousands of cases of children who claim to remember previous lives, by studying death, and subsequently the “biotechnological resurrection” of life, we can for the first time peak through the window, and offer a whole new knowledge base related to our place, and our interaction, with the very structure of reality.
We are entering a very exciting era of discovery and exploration.
About the author
Ira S. Pastor is the Chief Executive Officer of Bioquark Inc. (www.bioquark.com), an innovative life sciences company focusing on developing novel biologic solutions for human regeneration, repair, and rejuvenation. He is also on the board of the Reanima Project (www.reanima.tech)
h+ Magazine: Synthetic Biology — The True Savior of Mankind
Posted in biological, biotech/medical, disruptive technology, DNA, environmental, ethics, futurism, genetics, health, innovation, science, sustainability, transhumanism | Leave a Comment on h+ Magazine: Synthetic Biology — The True Savior of Mankind
Fear of scientists “playing god” is at the centre of many a plot line in science fiction stories. Perhaps the latest popular iteration of the story we all love is Jurassic World (2015), a film I find interesting only for the tribute it paid to the original Michael Crichton novel and movie Jurassic Park.
Full op-ed from h+ Magazine on 7 October 2015 http://hplusmagazine.com/2015/10/07/opinion-synthetic-biology-the-true-savior-of-mankind/
In Jurassic Park, a novel devoted to the scare of genetic engineering when biotech was new in the 1990s, the character of John Hammond says:
“Would you make products to help mankind, to fight illness and disease? Dear me, no. That’s a terrible idea. A very poor use of new technology. Personally, I would never help mankind.”
What the character is referring to is the lack of profit in actually curing diseases and solving human needs, and the controversy courted just by trying to get involved in such development. The goal to eradicate poverty or close the wealth gap between rich and poor nations offers no incentive for a commercial company.
Instead, businesses occupy themselves with creating entertainment, glamour products and perfume, new pets, and other superfluities that biotech can inevitably offer. This way, the companies escape not only moral chastisement for failing to share their technology adequately or make it freely available, but they can also attach whatever price tag they want without fear of controversy.
It is difficult for a well-meaning scientist or engineer to push society towards greater freedom and equality in a single country. It is even harder for such a professional to effect a great change over the whole world or improve the human condition the way transhumanists, for example, have intended.
Although discovery and invention continue to stun us all on an almost daily basis, such things do not happen as quickly or in as utilitarian a way as they should. And this lack of progress is deliberate. As the agenda is driven by businessmen who adhere to the times they live in, driven more by the desire for wealth and status than helping mankind, the goal of endless profit directly blocks the path to abolish scarcity, illness and death.
Today, J. Craig Venter’s great discoveries of how to sequence or synthesize entire genomes of living biological specimens in the field of synthetic biology (synthbio) represent a greater power than the hydrogen bomb. It is a power we must embrace. In my opinion, these discoveries are certainly more capable of transforming civilization and the globe for the better. In Life at the Speed of Light(2013), that is essentially Venter’s own thesis.
And contrary to science fiction films, the only threat from biotech is that humans will not adequately and quickly use it. Business leaders are far more interested in profiting from people’s desire for petty products, entertainment and glamour than curing cancer or creating unlimited resources to feed civilization. But who can blame them? It is far too risky for someone in their position to commit to philanthropy than to stay a step ahead of their competitors.
Even businessmen who later go into philanthropy do very little other than court attention in the press and polish the progressive image of the company. Of course, transitory deeds like giving food or clean water to Africans will never actually count as developing civilization and improving life on Earth, when there are far greater actions that can be taken instead.
It is conspicuous that so little has been done to develop the industrial might of poor countries, where schoolchildren must still live and study without even a roof over their heads. For all the unimaginable destruction that our governments and their corporate sponsors unleash on poor countries with bombs or sanctions when they are deemed to be threatening, we see almost no good being done with the same scientific muscle in poor countries. Philanthropists are friendly to the cause of handing out food or money to a few hungry people, but say nothing of giving the world’s poor the ability to possess their own natural resources and their own industries.
Like our bodies, our planet is no longer a sufficient vehicle for human dreams and aspirations. The biology of the planet is too inefficient to support the current growth of the human population. We face the prospect of eventually perishing as a species if we cannot repair our species’ oft-omitted disagreements with nature over issues of sustainability, congenital illness and our refusal to submit to the cruelties of natural selection from which we evolved.
Once we recognize that the current species are flawed, we will see that only by designing and introducing new species can suffering, poverty and the depletion of natural resources be stopped. Once we look at this option, we find already a perfect and ultimately moral solution to the threats of climate change, disease, overpopulation and the terrible scarcity giving rise to endless injustice and retaliatory terrorism.
The perfect solution could only be brought to the world by a heroic worker in the fields of biotech and synthetic biology. Indeed, this revolution may already be possible today, but fear is sadly holding back the one who could make it happen.
Someone who believes in changing the human animal with technology must believe in eradicating poverty, sickness and injustice with technology. For all our talk of equality and human rights in our rhetoric, the West seems determined to prevent poorer countries from possessing their own natural resources. A right guaranteed by the principles of modernization and industrialization, which appears to have been forgotten. Instead, we prefer to watch them being nursed by the richer countries’ monopolies, technology, and workers who are there cultivating, extracting, refining, or buying all their resources for them.
So, quite contrary to the promises of modernity, we have replaced the ideal of the industrialization of poor states with instead the vision of refugee camps, crude water wells, and food aid delivered by humanitarian workers to provide only temporary relief. In place of a model of development that was altruistic and morally correct, we instead glorify the image of non-Westerners as primitives who are impossible to help yet still we try.
The world’s poor have become not the focus of attention aimed at helping humanity, but props for philanthropists to make themselves look noble while doing nothing to truly help them. What we should turn to is not a return to the failed UN development agendas of the 1970s, which were flawed, but a new model entirely, and driven by people instead of governments and UN agencies.
It is high time that we act to help mankind altruistically, rather than a select few customers. The engineers and scientists of the world need to abandon the search for profit, if only for a moment. We should call on them to turn their extraordinary talent to the absolute good of abolishing poverty and scarcity. If they do not do this, we will talk about direct action to break free the scientific gifts they refused to share.
We live in courageous times. These are times of whistle-blowers, lone activists for the truth, and lone scientist-entrepreneurs who must be praised even if our profit-driven culture stifles their great works. And although we live in courageous times, we seem not yet brave enough to take real action to overcome the human disaster.
###
Synthetic biology image from https://www.equipes.lps.u-psud.fr/TRESSET/research8.html
(A) Enclosure of three red-fluorescent 200-nm spheres inside a “giant” liposome labeled with DiO. A wideband ultraviolet excitation filter was used for the simultaneous observation of these two differently stained species. Images were digitally postprocessed to balance the colors and to adjust their brightness at an equal level. (B) Trajectories of the particles. They were free to move but did not pass through the membrane. © GFP entrapped by a “giant” liposome. To get rid of noncaptured proteins, the solution was filtered by dialysis in such a way that the fluorescence background level became negligible with respect to the liposome interior. (D) Fluorescence photographs of λ-DNA-loaded liposome. λ-DNA was stained with SYBR Green, while DiI (red emission) was incorporated to liposome membrane. Liposome was observed through a narrow-band blue excitation filter (suitable for SYBR Green). (E) Same as previously with a wideband green excitation filter (suitable for DiI). Because of a low fluorescence response, part D was digitally enhanced in terms of brightness and contrast. In comparison, part E was darkened to present a level similar to part D. These pictures were taken at an interval of ~1 s, just the time to switch the filters. (E) Fluorescence picture of λ-DNA-loaded liposomes. Green dots stand for λ-DNA molecules, and lipids are labeled in red. A wideband blue excitation filter was used for this bicolor imaging, and a high-sensitivity color CCD camera captured it. [Anal. Chem. 77 (2005) 2795]